Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 Daily cadence·165 episodes·Last published 5d ago - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 16 epsHosts
Recent guests
Recent episodes
Looking Forward: Biotech in the Balance? Dr. Jeremy Levin, Bioentrepreneur & Former Chair, BIO
Jun 21, 2026
44m 50s
How 200 Snake Bites Became an Antivenom...Dr. Jake Glanville, Founder, CEO, Chair of Centivax
Jun 16, 2026
34m 14s
Hospital at Home? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent
Jun 9, 2026
8m 34s
Personalized Vaccines for Treating Glioblastoma? Jay Hartenbach & Dr. Will Decker, Diakonos Oncology
May 29, 2026
24m 43s
A Not-in-the-Textbooks Discovery for Glioblastoma, Jay Hartenbach & Dr. Will Decker, Diakonos Oncology
May 29, 2026
24m 04s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
Resolving iTunes ID\u2026 if this persists, the podcast may not be indexed on Apple Podcasts.
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/21/26 |  Looking Forward: Biotech in the Balance? Dr. Jeremy Levin, Bioentrepreneur & Former Chair, BIO | On this episode of BioTech Nation...The Biotech landscape is ever-evolving - but where are we headed?? Dr. Jeremy Levin, Physician, Bioentrepreneur, and Former Chair of BIO, joins Moira to talk about the future of Biotech from the front lines of the industry - from understanding the global Bioeconomy, to preparing for the next pandemic, and how government policy is impacting innovation. His book is, "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust". | 44m 50s | ||||||
| 6/16/26 |  How 200 Snake Bites Became an Antivenom...Dr. Jake Glanville, Founder, CEO, Chair of Centivax | This week on BioTech Nation, a call to a man who survived hundreds of venomous snake bites helps inspire the development of an antivenom vaccine. Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider’s view of this Biotech Breakthrough – from the first telephone call through each significant step, all leading to the first breakthrough generalized antivenom vaccine in 125 years. | 34m 14s | ||||||
| 6/9/26 |  Hospital at Home? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent✨ | remote healthcarehospital-at-home+3 | Dr. Daniel Kraft | Tech Nation | — | hospital-at-homeremote healthcare+3 | — | 8m 34s | |
| 5/29/26 |  Personalized Vaccines for Treating Glioblastoma? Jay Hartenbach & Dr. Will Decker, Diakonos Oncology✨ | cancer treatmentimmunotherapy+3 | Dr. Will DeckerJay Hartenbach | new drugDiakonos Oncology | Chicago | personalized vaccinescancer immunotherapy+3 | — | 24m 43s | |
| 5/29/26 | A Not-in-the-Textbooks Discovery for Glioblastoma, Jay Hartenbach & Dr. Will Decker, Diakonos Oncology | On this episode of BioTech Nation, Dr. Will Decker and Jay Hartenbach join Moira to talk about Diakonos Oncology's unique approach to cancer immunotherapy, and how a discovery made over two decades ago started it all. Now, with a new drug entering Phase II human trials for Glioblastoma treatment, that discovery could mean a pathway to treating aggressive cancers... | 24m 04s | ||||||
| 5/28/26 |  Two Drug Approvals in Two Years...Michael Metzger, CEO, Syndax Pharmaceuticals✨ | cancer treatmentdrug approval+4 | Michael Metzger | Syndax PharmaceuticalsASCO+2 | Chicago | Syndax Pharmaceuticalsdrug approval+5 | — | 13m 11s | |
| 5/26/26 |  Fighting Hard-to-Treat Cancers...Dan Schmitt, President & CEO, Actuate Therapeutics✨ | cancer treatmentbiotechnology+3 | Dan Schmitt | new kind of drugActuate Therapeutics | Chicagoadult pancreatic cancer+1 | cancerbiotech+6 | — | 16m 37s | |
| 5/19/26 |  A Different Way to Treat Parkinson's...Dr. Jonas Hannestad & Dr. Joanne Taylor, Gain Therapeutics✨ | Parkinson's treatmentbiotechnology+3 | Dr. Jonas HannestadDr. Joanne Taylor | Gain TherapeuticsBioTech Nation | — | Parkinson'sGain Therapeutics+4 | — | 13m 14s | |
| 5/12/26 |  A Life Decoded...A 2007 Interview with Dr. J. Craig Venter✨ | biotechnologygenome decoding+3 | Dr. J. Craig Venter | A Life Decoded: My Genome, My Life | — | Dr. J. Craig Venterhuman genome+3 | — | 17m 32s | |
| 5/12/26 | Looking Back: A 2007 Interview with Dr. J. Craig Venter | With the recent passing of Dr. J. Craig Venter, biotech scientist and entrepreneur, we look back at Moira and David Ewing Duncan's 2007 interview with Dr. Venter. The occasion for the interview was the publication of his autobiography: "A Life Decoded: My Genome, My Life." Dr. Craig Venter was known for catalyzing the race to decode the human genome, and at the time of the interview had just decoded his own complete DNA and published it on the Internet. | 16m 53s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 5/5/26 |  50 Years of Genentech...Ashley Magargee, CEO, Genentech✨ | biotechGenentech+3 | Ashley Magargee | Genentech | — | Genentechbiotech company+3 | — | 32m 39s | |
| 4/28/26 |  The Global Diversity of Human Genetics...Andrew Farnum and Sarah LeBaron von Baeyer, Variant Bio✨ | human geneticsindigenous tribes+4 | Andrew FarnumSarah LeBaron von Baeyer | Variant Bio | — | genetic dataindigenous tribes+4 | — | 28m 29s | |
| 4/21/26 |  New treatment being tested for pre-term babies... Dr. Marc Salzberg, CEO and Chief Medical Officer, Airway Therapeutics✨ | preterm babiesmedical treatment+3 | Dr. Marc Salzberg | Airway Therapeutics | — | preterm babiestreatment+3 | — | 22m 20s | |
| 4/21/26 | Testing New Drugs for Pre-Term Babies... Dr. Marc Salzberg, CEO and Chief Medical Officer, Airway Therapeutics | Dr. Marc Salzberg, CEO & Chief Medical Officer of Airway Therapeutics, talks about what they are doing to help preterm babies. It may all boil down to delivering these babies a single protein as soon as they are born. | 21m 40s | ||||||
| 4/14/26 |  Now, Near, Next...Dr. Daniel Kraft, Tech Nation Health Chief Correspondent✨ | healthcare innovationbiotech breakthroughs+3 | Dr. Daniel Kraft | Tech NationAI+1 | — | healthcareinnovation+5 | — | 13m 14s | |
| 4/7/26 |  Changing the Future of Cancer Surgery...A 2017 Interview with Dr. Phil Low, Professor & Biotech Entrepreneur✨ | cancer surgerybiotech+3 | Dr. Phil Low | Purdue Universityfluorescence-guided surgery | — | cancer treatmentbiotech entrepreneur+3 | — | 23m 23s | |
| 3/31/26 |  Who is Medically Qualified to Go to Space??? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent✨ | space travelmedical qualifications+3 | Dr. Daniel Kraft | Tech Nation | — | spacemedical qualification+4 | — | 9m 58s | |
| 3/24/26 |  Big Tech & Healthcare...Dr. Marschall Runge, Author, "The Great Healthcare Disruption"✨ | healthcarebig tech+3 | Dr. Marschall Runge | University of Michigan Medical SchoolThe Great Healthcare Disruption | — | healthcare disruptionbig tech+3 | — | 42m 11s | |
| 3/17/26 |  Regaining Function After Spinal Cord Injury: A New Path Forward? Dr. Adam Rogers, CEO, NervGen Pharma✨ | spinal cord injurytreatment+3 | Dr. Adam Rogers | NervGen Pharma | — | spinal cord injuryNervGen Pharma+5 | — | 22m 05s | |
| 3/17/26 | Regaining Function? Years Post-Spinal Cord Injury? Dr. Adam Rogers, CEO, NervGen Pharma | On this week’s BioTech Nation, Moira speaks with Dr. Adam Rogers, CEO of NervGen Pharma, about a new treatment that’s showing significant trial results for patients with spinal cord injuries. While typically, patient progress is defined by the early months of recovery after the injury, some trial participants have seen increased function as much as 10 years post-trauma. | 21m 26s | ||||||
| 3/10/26 |  A New Approach to Treating ALS...Dr. Arun Swaminathan, CEO, Coya Therapeutics✨ | ALS treatmentclinical trials+3 | Dr. Arun Swaminathan | ALSParkinson’s+3 | — | ALSCoya Therapeutics+3 | — | 18m 36s | |
| 3/3/26 |  The Future of Early Cancer Screening...Dr. Daniel Kraft, Tech Nation Health Chief Correspondent✨ | cancer screeningdiagnostics+3 | Dr. Daniel Kraft | Tech Nation Health | — | cancerscreening+5 | — | 7m 38s | |
| 2/24/26 |  AI in the Exam Room, Dr. Robert Wachter, Author, "A Giant Leap" | On this week’s Biotech Nation, how doctors and hospitals are using AI, and how it could change the practice of medicine. Moira speaks with Dr. Robert Wachter about his book, “A Giant Leap: How AI is Transforming Healthcare and What That Means for Our Future”. | 28m 32s | ||||||
| 2/17/26 |  ChatGPT...for Healthcare? Dr. Daniel Kraft, Tech Nation Health Chief Correspondent | You may already use "Dr. ChatGPT" to answer your medical questions... but now, OpenAI has announced the rollout of ChatGPT Health and OpenAI for Healthcare. Dr. Daniel Kraft has the latest on how each platform will work, and what happens with the health data you share. | 8m 45s | ||||||
| 2/10/26 |  AI Biology - Chan-Zuckerberg Style? Dr. Shana Kelley, President of Bioengineering, Chan-Zuckerberg Initiative | This week on BioTech Nation, what is AI-Powered Biology? Dr. Shana Kelley, President of Bioengineering and Head of Biohub, Chicago for the Chan-Zuckerberg Initiative, discusses how AI can be used to accelerate research, and what this could mean for the future. | 25m 24s | ||||||
Showing 25 of 176
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.